Identification of the anti-neoplastic target of bioactive FTY720 analogs
生物活性 FTY720 类似物抗肿瘤靶点的鉴定
基本信息
- 批准号:8568587
- 负责人:
- 金额:$ 19.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-01 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAffinityAffinity LabelsAgonistAlkynesAnimal ModelAntineoplastic AgentsArchitectureAwardAzidesBindingBioavailableBiochemicalBiologicalBiological AssayBiologyBiotinBradycardiaCancer ModelCancer PatientCellsCeramidesCharacteristicsChemicalsChemistryCoat Protein Complex IComplexCopperCoupledDataDevelopmentDiazomethaneDoseDose-LimitingDown-RegulationDrug CombinationsDrug TargetingDrug resistanceEmployee StrikesExhibitsFDA approvedFundingGrowthHumanHydrocarbonsIn VitroLigandsLymphocyteLymphoidMalignant NeoplasmsMass Spectrum AnalysisModelingMolecularMolecular TargetMultiple SclerosisMusNeoplasm MetastasisNutrientOralOrganPatientsPermeabilityPharmaceutical PreparationsPrimary NeoplasmProbabilityProtein Phosphatase 2A Regulatory Subunit PR53ProteinsProtocols documentationPublishingPyrrolidinesRadiolabeledReactionReceptor ActivationSeriesSpecificitySphingolipidsSphingomyelinsSphingosineSphingosine-1-Phosphate ReceptorStagingStreptavidinStructure-Activity RelationshipTechniquesTestingTherapeuticToxic effectTumor Suppressor ProteinsWaterWorkaffinity labelinganalogappendagebasecancer cellcancer initiationcancer therapycancer typecatalystcrosslinkdesigneffective therapyfunctional groupgel electrophoresisin vivoinhibitor/antagonistkillingsleukemianeoplasticnovelnovel strategiespatient populationpreventprotein complexpublic health relevancepyrrolidineradiotracersuccesstherapeutic developmenttumor
项目摘要
DESCRIPTION (provided by applicant): SUMMARY FTY720 is FDA-approved oral treatment for multiple sclerosis (MS). At the dose used to treat MS, FTY720's effects on sphingosine-1-phosphate receptors result in the sequestration of lymphocytes in secondary lymphoid organs. At much higher doses, many groups have demonstrated that FTY720 is a selective and effective anti-neoplastic agent that works against a wide variety of tumor types. In mouse cancer models at 5-10 mg/kg, FTY720 inhibits the growth of both primary tumors and metastases while exhibiting minimal toxicity. Despite this striking success in animal models, FTY720 cannot be tested in human cancer patients because it triggers profound bradycardia by activating S1P receptors 1 and 3 before the anti-neoplastic dose is reached. However, we have recently demonstrated that the anti-neoplastic effect of FTY720 occurs through an S1P receptor-independent mechanism that includes nutrient transporter down-regulation. While FTY720 analogs that fail to activate S1P receptors have promising anti-neoplastic activity and therapeutic potential, the molecular target of FTY720 in cancer models remains unknown. In this proposal, we will use a chemical biology approach to identify the target of FTY720 and its anti-neoplastic analogs in cancer cells. This project has two Specific Aims: 1) Generate photo-affinity labeling probes from FTY720 analogs that are active in intact cells, and 2) Isolate proteins that specifically interact with the probes using a series of negative controls to identify non-specific binding partners. These probes will include a diazirine to allow UV-crosslinking to the target and an alkyne to covalently couple a biotin to the probe-target complex via "click" chemistry. Determining the molecular target for FTY720 and its analogs in cancer models is a critical step in the development of this novel approach to cancer therapy because it will allow us to: 1) define the molecular characteristics of tumors that will be susceptible to this therapeutic approach so that drugs can be tested in the correct patient populations, 2) uncover potential mechanisms of resistance to these drugs, 3) anticipate potential toxicities, 4) make predictions about drug combinations that are likely to be synergistic, and 5) test our model for how these compounds selectively kill cancer cells using standard molecular and biochemical techniques.
描述(由申请人提供):摘要FTY 720是FDA批准的多发性硬化症(MS)的口服治疗。在用于治疗MS的剂量下,FTY 720对鞘氨醇-1-磷酸受体的作用导致次级淋巴器官中淋巴细胞的隔离。在更高的剂量下,许多研究小组已经证明FTY 720是一种选择性和有效的抗肿瘤药物,可以对抗各种肿瘤类型。在5-10 mg/kg的小鼠癌症模型中,FTY 720抑制原发性肿瘤和转移瘤的生长,同时表现出最小的毒性。尽管在动物模型中取得了惊人的成功,但FTY 720不能在人类癌症患者中进行测试,因为它在达到抗肿瘤剂量之前通过激活S1 P受体1和3引发严重的心动过缓。然而,我们最近证明FTY 720的抗肿瘤作用是通过S1 P受体非依赖性机制发生的,包括营养转运蛋白下调。虽然不能激活S1 P受体的FTY 720类似物具有很好的抗肿瘤活性和治疗潜力,但FTY 720在癌症模型中的分子靶点仍然未知。在本提案中,我们将使用化学生物学方法来鉴定FTY 720及其抗肿瘤类似物在癌细胞中的靶点。该项目有两个具体目标:1)从FTY 720类似物中产生在完整细胞中具有活性的光亲和标记探针,2)使用一系列阴性对照分离与探针特异性相互作用的蛋白质,以鉴定非特异性结合伴侣。这些探针将包括允许与靶标UV交联的二氮杂环丙烯和通过“点击”化学将生物素共价偶联至探针-靶标复合物的炔。确定FTY 720及其类似物在癌症模型中的分子靶点是开发这种新型癌症治疗方法的关键一步,因为它将使我们能够:1)确定对这种治疗方法敏感的肿瘤的分子特征,以便可以在正确的患者群体中测试药物,2)揭示对这些药物耐药的潜在机制,3)预测潜在的毒性,4)预测可能具有协同作用的药物组合,5)使用标准分子和生物化学技术测试我们的模型,以了解这些化合物如何选择性地杀死癌细胞。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Aimee L Edinger其他文献
Aimee L Edinger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Aimee L Edinger', 18)}}的其他基金
A novel strategy to overcome drug resistance in cancer
克服癌症耐药性的新策略
- 批准号:
10319166 - 财政年份:2021
- 资助金额:
$ 19.45万 - 项目类别:
A novel strategy to overcome drug resistance in cancer
克服癌症耐药性的新策略
- 批准号:
10609389 - 财政年份:2021
- 资助金额:
$ 19.45万 - 项目类别:
Defining the role of macropinocytosis in solid tumor growth and therapeutic resistance
定义巨胞饮作用在实体瘤生长和治疗耐药中的作用
- 批准号:
10368053 - 财政年份:2020
- 资助金额:
$ 19.45万 - 项目类别:
Defining the role of macropinocytosis in solid tumor growth and therapeutic resistance
定义巨胞饮作用在实体瘤生长和治疗耐药中的作用
- 批准号:
10640820 - 财政年份:2020
- 资助金额:
$ 19.45万 - 项目类别:
Identification of the anti-neoplastic target of bioactive FTY720 analogs
生物活性 FTY720 类似物抗肿瘤靶点的鉴定
- 批准号:
8710117 - 财政年份:2013
- 资助金额:
$ 19.45万 - 项目类别:
Effects of sphingolipids on nutrient transporter expression and bioenergetics
鞘脂对营养转运蛋白表达和生物能学的影响
- 批准号:
8541863 - 财政年份:2010
- 资助金额:
$ 19.45万 - 项目类别:
Effects of sphingolipids on nutrient transporter expression and bioenergetics
鞘脂对营养转运蛋白表达和生物能学的影响
- 批准号:
7769039 - 财政年份:2010
- 资助金额:
$ 19.45万 - 项目类别:
Effects of sphingolipids on nutrient transporter expression and bioenergetics
鞘脂对营养转运蛋白表达和生物能学的影响
- 批准号:
8146063 - 财政年份:2010
- 资助金额:
$ 19.45万 - 项目类别:
Effects of sphingolipids on nutrient transporter expression and bioenergetics
鞘脂对营养转运蛋白表达和生物能学的影响
- 批准号:
8317814 - 财政年份:2010
- 资助金额:
$ 19.45万 - 项目类别:
Effects of sphingolipids on nutrient transporter expression and bioenergetics
鞘脂对营养转运蛋白表达和生物能学的影响
- 批准号:
8730169 - 财政年份:2010
- 资助金额:
$ 19.45万 - 项目类别:
相似海外基金
Affinity labels of steroid sulfatase
类固醇硫酸酯酶的亲和标记
- 批准号:
399876-2010 - 财政年份:2010
- 资助金额:
$ 19.45万 - 项目类别:
University Undergraduate Student Research Awards
Synthese von Strukturanaloga sowie von affinity labels des Naturstoffs Salicylihalamid A zur Untersuchung von Struktur-Wirkungsbeziehungen sowie zur Charakterisierung der Interaktion von Salicyclihalamiden mit ihrem biologischen Target
合成天然产物水杨酰卤酰胺 A 的结构类似物和亲和标记,以研究结构-活性关系并表征水杨酰卤酰胺与其生物靶标的相互作用
- 批准号:
5278706 - 财政年份:2000
- 资助金额:
$ 19.45万 - 项目类别:
Research Fellowships














{{item.name}}会员




